There needs to be more transparency in drug pricing — including looking at the middlemen — but when it comes to the controversy about Mylan's pricing of its EpiPen, the company still has a lot of questions to answer, Sen. Charles "Chuck" Grassley, R-Iowa, said Thursday.
"Transparency and things of that nature I think are very, very important but in this particular instance we've got one company with a monopoly on the product going up more than 400 percent," the chairman of the Senate Judiciary Committee said in an interview with CNBC's "Power Lunch."
The drug, used to counteract a potentially fatal allergic reaction, has a retail cost of more than $600. On Thursday, the company announced it increased rebates to many consumers.
Mylan CEO Heather Bresch told CNBC on Thursday that she too was "frustrated" over the EpiPen furor, noting that the price reflects a system where the drug goes through middlemen before it gets to patients.
She also said she has reached out to Grassley to talk about the issue, in response to a letter the senator sent on Monday requesting information about the sharp price increases.